Zydus Cadila files NDA for Saroglitazar Magnesium

NASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for the treatment of NASH. aroglitazar Mg has previously demonstrated improvement in both liver enzymes along with favorable effects on lipid and glycemic indices in patients with nonalcoholic fatty liver disease in Phase II clinical trials.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news

Related Links:

In this study, we evaluated the diagnostic value of serum Golgi protein 73 (GP73) for hepatic necroinflammatory damage in patients with NASH. Methods: The clinical data of 201 patients with NASH diagnosed by liver biopsy according to the Brunt staging system were collected retrospectively. The in situ expression of GP73 protein was measured by immunohistochemistry. The receiver operating characteristic (ROC) curve was used to calculate the area under the ROC curve (AUROC) of serum GP73 for diagnosing hepatic necroinflammatory damage. Results: The serum GP73 levels of NASH patients increased with the aggravation of ...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Conditions:   Steatohepatitis, Nonalcoholic;   Hemosiderosis;   Overweight Adolescents;   Obesity, Childhood;   Liver Steatosis Intervention:   Sponsor:   The Geneva Foundation Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractBackground/ObjectiveNon ‐alcoholic fatty liver disease (NAFLD) is more and more common in patients with type 2diabetes mellitus (T2DM). Currently, some researches have found that Sodium glucose co‐ transporter2 (SGLT2) inhibitors, a new hypoglycemic drug, can improve nonalcoholic fatty liver besides hypoglycemic effect . Thus, we undertook a meta‐analysis of randomized controlled trials (RCTs) to evaluate the efficacy of SGLT2 inhibitors on the treatment of NAFLDMethodsPubMed, Embase and the Cochrane Library were searched for RCTs of SGLT2 inhibitors in patients with NAFLD and T2DM up to Oct1, 2019. Differenc...
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research
AbstractClostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea while nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The aim of this study was to determine whether NAFLD increases susceptibility to CDI. A retrospective cohort study included patients ≥ 65 years, treated with antimicrobial therapy ≥ 24 h, and hospitalized ≥ 72 h in a 36-month period. Three-hundred fourteen patients were included; 83 with NAFLD and 231 controls. Except for diabetes mellitus (37.35% vs. 25.11%,p = 0.0462) and obesity (18.07% vs. 8.23%,p = 0.0218) that...
Source: European Journal of Clinical Microbiology and Infectious Diseases - Category: Microbiology Source Type: research
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
Psoriasis is a chronic, systemic immune-mediated disease characterized by development of erythematous, indurated, scaly, pruritic plaques on the skin. Psoriasis is frequently associated to comorbidities, including psoriatic arthritis, cardiovascular diseases, diabetes mellitus, obesity, non-alcoholic fatty liver disease, and inflammatory bowel diseases. In this review, we discuss the pathophysiological relationship between psoriasis and cardio-metabolic comorbidities and the importance of therapeutic strategies to reduce systemic inflammation in patients with moderate-to-severe psoriasis. Pathogenesis of psoriasis and its ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
CHD is reported to be the primary cause of death in patients with NAFLD. Genetic susceptibility genes contribute to the developmental risk of NAFLD or CHD. Whether the genetic factors could affect the risk of ...
Source: Lipids in Health and Disease - Category: Lipidology Authors: Tags: Research Source Type: research
Non-alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease in the developed world, is characterized by hepatic fat accumulation in the absence of significant alcohol or hepatotoxic drug consumption, hereditary diseases and viral infections.1 The multifactorial pathogenesis of NAFLD is associated with lifestyle habits, nutritional factors and genetics. Gene polymorphisms, implicated in fatty acid metabolism are described.1 In case of unexplained NAFLD, further investigations are required to determine the origin of the disease.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
Authors: Valentí V, Cienfuegos JA, Becerril Mañas S, Frühbeck G Abstract Bariatric-metabolic surgery is the safest, most effective and long-lasting treatment for obesity and its associated co-morbidities, whether they be metabolic (type 2 diabetes, hyperlipidemia non-alcoholic fatty liver disease) or cardiovascular (myocardial infarction, stroke). Due to the obesity pandemic, bariatric-metabolic surgery is the second most frequent intra-abdominal procedure and the gastroenterologist and the surgeon must be aware of the physiologic changes caused by the anatomic reconfiguration following surgery. ...
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research
The objective of this study was to evaluate the distribution of socioeconomic deprivation, measured using an area-level proxy, in pediatric patients with known NAFLD and to determine whether deprivation is associated with liver disease severity. Methods: Retrospective study of patients
Source: Journal of Pediatric Gastroenterology and Nutrition - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
More News: Biotechnology | Clinical Trials | Fatty Liver Disease (FLD) | Liver | Liver Disease | Magnesium | Non-alcoholic Fatty Liver Diseases (NAFLD) | Pharmaceuticals | Urology & Nephrology